Replies to post #58747 on DNAprint Genomics (DNAG)

[stockhlder101]

as soon as M2GEN comes to life...PONV and many other things can start DNAPrint earning money!

"PONV ready? Emend with a test. Enviously green, eh?....

EMEND? (aprepitant) Helps Prevent Nausea/Vomiting for Breast Cancer Patients

the regimen including EMEND (day 1: EMEND 125 mg one hour before chemotherapy, ondansetron 8 mg 30-60 minutes before chemotherapy

EMEND? is a registered trademark of Merck & Co

http://www.medicalnewstoday.com/medicalnews.php?newsid=23074


Ondansetron
Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Ondansetron response. Ondansetron is an anti-emetic for the alleviation of post-operative nausea and vomiting (PONV), but normal doses of the drug do not elicit the desired effect in some patients. A genetic test for predicting Ondansetron response could help reduce extreme discomfort many patients feel after surgery.

March 29, 2004 DNAPrint™ genomics, Inc. Forms Joint Research Program with the H. Lee Moffitt Cancer Center and Research Institute"